Evaluative Clinical Sciences

Dr. Nam is head of the Genitourinary Cancer Site Group, Odette Cancer Centre, Sunnybrook Health Sciences Centre. He holds the Ajmera Family Chair in Urologic Oncology. He has expertise in uro-oncology and cancer genetics.

His research interests include the genetic epidemiology of prostate cancer and new biomarker discovery for prostate cancer diagnosis. He holds multiple operating grants in prostate cancer research from the national granting agencies National Cancer Institute of Canada and Canadian Institute of Health Research (CIHR), and has published many papers in the field of prostate cancer genetics and biomarkers. Highlights of his research awards include a CIHR Career Award, a Early Researcher Award from the Ministry of Research and Innovation of Ontario, and the Royal College of Physicians and Surgeons Medal Award in Surgery for his work in prostate cancer genetics.

He has given numerous lectures on prostate cancer biomarkers and genetics at national and international meetings and universities. Dr. Nam's clinical practice primarily consists of the surgical treatment of patients with urologic malignancies, including prostate, bladder, kidney and testicular cancer.

Education:

• MD, 1995, University of Toronto, Canada
• M.Sc., 1999, clinical epidemiology, U of T, Canada
• FRCS(C), 2001, Royal College of Physicians and Surgeons of Canada

Appointments and Affiliations:

• Associate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
• Head, Genitourinary Cancer Care, Odette Cancer Centre, Sunnybrook Health Sciences Centre
• Ajmera Family Chair in Urologic Oncology
• Professor, department of surgery, U of T
• Associate member, U of T School of Graduate Studies
• Faculty, department of health policy, management and evaluation, U of T

Research Foci:

• Prostate cancer
• Genetic epidemiology
• Biomarkers
• Diagnosis
• Prognosis
• Non-experimental methods

Research Summary:

Dr. Nam conducts studies in the field of prostate cancer genetics evaluating host and tumour factors. He also conducts evaluative studies in prostate cancer screening tools called nomograms and population-based issues related to prostate cancer survivorship.

Selected Publications:

See current publications list at PubMed.

Related News and Stories:

• In search of a sign: Newly identified prostate cancer genes may aid patient prognosis (June 11, 2014)
• Weigh the risks of prostate cancer treatment: Patients should discuss complications with their doctor (Jan. 17, 2014)
• Big grant for small science: Nanotech microchip could change screening for prostate cancer (June 3, 2011)
• Prostate cancer risk online tool supports more dialogue (Feb. 4, 2008)
• The penny drops: Sunnybrook Research Institute scientists give Canadian Cancer Society leaders a glimpse of where the money goes (April 4, 2007)
• Hybrid gene targets high relapse risk in prostate cancer patients (Jan. 23, 2007)
• On to the finish line: Sunnybrook scientist sprints forward in a bid to improve the course for prostate cancer testing (Jan. 9, 2007)

Related Links:

• U of T profile, department of surgery